Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Genomic Urine Testing Market Through 2034?
The market size for genomic urine testing has seen a swift expansion in the past few years. There will be a significant increase from $0.9 billion in 2024 to $1.01 billion in 2025, with a compound annual growth rate (CAGR) of 11.9%. Factors like the growing occurrence of urologic cancers, the heightened demand for early cancer detection, increased knowledge about precision medicine, the increasing rate of genetic disorders, and enhanced investments in biomarker discovery are responsible for the growth observed in the historic period.
In the coming years, the size of the genomic urine testing market is projected to experience rapid expansion. It’s expected to reach$1.61 billion by 2029 at a compound annual growth rate (CAGR) of 12.4%. The anticipated growth during the forecast period can be credited to the increasing adoption of liquid biopsy methods, the escalating focus on tailor-made medicine, the swelling burden of chronic kidney ailments, the heightened emphasis on home-based diagnostic testing solutions, and the escalating use of multi-omics techniques in urine testing. The forecast period will also witness major trends like the creation of non-intrusive diagnostic routes, the development of highly sensitive test panels, the integration of machine learning workflows, advancements in urine exosome isolation, and innovations in single-cell urine sequencing.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp
What External and Internal Drivers Are Contributing to the Growth of theGenomic Urine Testing Market?
The escalation in chronic kidney disease cases is predicted to fuel expansion of the genomic urine testing market. The term “chronic kidney disease” implies a situation where the kidneys are impaired and unable to effectively cleanse the blood, causing a waste accumulation and excess fluid. The increasing occurrence of diabetes, which damages the kidney blood vessels due to high blood sugar, elevates the chronic kidney disease burden, undermining the kidney’s waste filtering capability. Genomic urine testing helps manage chronic kidney disease by offering premature detection of genetic markers, enabling prompt interventions and individualized treatment schemes. It improves patients’ prognosis by allowing more precise surveillance and curtailing disease expansion. For instance, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in June 2024 that chronic kidney disease (CKD) mortality rates had escalated by 4.2% in 2021 to 6.2% in 2022. Thus, the mounting burden of chronic kidney disease stimulates the growth of the genomic urine testing market.
What Segment Types Define the Genomic Urine Testing Market Structure?
The genomic urine testingmarket covered in this report is segmented –
1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing; Ribonucleic Acid (RNA) Testing; Microbial Testing; Epigenetic Testing
2) By Distribution Channel: Hospital Pharmacies; Mail Order Pharmacies; Speciality Pharmacies
3) By Application: Cancer Diagnosis; Infectious Diseases; Genetic Disorder Screening; Health Monitoring
4) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutions; Other End Users
Subsegments:
1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis; Somatic Mutation Detection; Copy Number Variation (CNV) Testing; Single Nucleotide Polymorphism Analysis
2) By Ribonucleic Acid Testing: Gene Expression Profiling; Messenger Ribonucleic Acid Analysis; Non-coding Ribonucleic Acid Detection; Fusion Transcript Detection
3) By Microbial Testing: Urinary Microbiome Profiling; Pathogen Identification; Antimicrobial Resistance Gene Detection; Quantitative Microbial Load Analysis
4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis; Histone Modification Profiling; Chromatin Accessibility Testing
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23408&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Genomic Urine Testing Market?
North America was the largest region in the genomic urine testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Genomic Urine Testing Market?
Key players in the genomic urine testing market are focusing on the creation of groundbreaking solutions like next-generation sequencing, to enhance the precision, sensitivity and early identification capabilities of non-invasive diagnostic tests for a variety of ailments. Next-generation sequencing (NGS) is a superior DNA sequencing technology that facilitates quick, precise, and extensive examination of genetic material by simultaneously sequencing millions of DNA fragments. For example, in May 2023, the US-based biotechnology firm, Convergent Genomics Inc., introduced the genomic urine test UroAmp. This test utilizes next-generation DNA sequencing to recognize mutations in 60 genes related to bladder cancer, allowing for early detection, possibly up to 12 years prior to the manifestation of clinical symptoms. This provides comprehensive genetic insights that aid in diagnosis, treatment choices, and tracking recurrence, delivering higher accuracy compared to old-fashioned methods like cytology and cystoscopy.
View the full report here:
https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report
What Is the Definition of the Genomic Urine Testing Market?
Genomic urine testing is a non-invasive diagnostic method that analyzes genetic material present in urine to detect specific biomarkers related to diseases, such as cancer, infections, or genetic disorders. It combines genomics with advanced molecular techniques to identify mutations, gene expression patterns, or microbial deoxyribonucleic acid (DNA). The primary purpose is early detection, monitoring, and personalized treatment planning for various health conditions.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23408
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model